Beranda › Limfoma Folikuler › New York › New York City
Uji klinis Limfoma Folikuler di New York City, NY
24 studi untuk Limfoma Folikuler mencari peserta di lokasi sekitar New York City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Menerima pesertaFase 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Menerima pesertaFase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Menerima pesertaFase 1/2
- Research Site, New York
- Research Site, New York
Epco, Zanu, Ritux for R/R FL or MZL
Menerima pesertaFase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Menerima pesertaFase 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Menerima pesertaFase 1/2
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Menerima pesertaFase 1
- Columbia University, New York
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Menerima pesertaFase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Menerima pesertaFase 2
- Research Site, New York
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Menerima pesertaFase 3
- Mount Sinai Medical Center, New York
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Menerima pesertaFase 3
- Icahn School of Medicine at Mt Sinai, New York
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Menerima pesertaFase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Menerima pesertaFase 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- dan 1 lainnya
A Study of ARC-02 in B-cell NHL
Menerima pesertaFase 1
- NYU Langone, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Menerima pesertaFase 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
Menerima peserta
- New York State Psychiatric Institute (NYSPI) / Substance Treatment and Research Service (STARS), New York
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Menerima pesertaFase 2
- Memorial Sloan Kettering Cancer Center, New York
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Menerima pesertaFase 1
- Memorial Sloan Kettering Cancer Center - Bergen, New York
Chronic CED of TPT for Recurrent Malignant Glioma
Menerima pesertaFase 1
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Menerima pesertaFase 2
- Icahn School of Medicine at Mount Sinai Hospital, New York
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Menerima pesertaFase 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Menerima pesertaFase 3
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of SGR-1505 in Mature B-Cell Neoplasms
Menerima pesertaFase 1
- Weill Cornell, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, New York
Uji klinis Limfoma Folikuler di kota lain
- Milwaukee, WI19 studi
- Nashville, TN18 studi
- Houston, TX18 studi
- Boston, MA17 studi
- Baldwin Park, CA16 studi
- Seattle, WA15 studi
- Durham, NC15 studi
- Salt Lake City, UT13 studi
- Columbus, OH13 studi
- Chicago, IL12 studi
- San Antonio, TX12 studi
- Philadelphia, PA12 studi
Studi lain di New York City
- Kanker Payudara136 studi
- Kanker Paru Non-Sel Kecil121 studi
- Kanker (semua jenis)109 studi
- Kanker Prostat103 studi
- Kanker Metastatik93 studi
- Kanker Kolorektal78 studi
- Kanker Ovarium69 studi
- Kanker Paru60 studi
- Mieloma Multipel60 studi
- Kanker Pankreas60 studi
- Kanker Endometrium52 studi
- Leukemia Mieloid Akut51 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.